Screening women for breast cancer in their 40s rather than their 50s could save lives, say the authors of a new Lancet Oncology study, although that finding has been challenged
Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker De
Novartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, one of a crop of new drugs that the company thinks have blockbuster sa
